Caristo Diagnostics Appoints New CCO and CFO to Accelerate AI Scaling

David Vort joins as Chief Commercial Officer, bringing a history of scaling high-growth medical technology firms. His tenure includes a decade at iRhythm Technologies, where he guided the company from a startup to a multi-hundred-million-dollar revenue business, including its 2016 public offering. He most recently directed commercialization for Cytovale’s sepsis diagnostic. Chris Louk, stepping in as Chief Financial Officer, moves to Caristo from Piper Sandler, where he served as Vice President of Healthcare Investment Banking. Louk was instrumental in major medtech transactions, including the 1.5 billion dollar sale of OrganOx to Terumo Corporation.

These leadership changes support the company's momentum following the 2025 FDA clearance of its CaRi-Plaque technology. While the firm expands its U.S. presence, its CaRi-Heart platform, which utilizes the patented Fat Attenuation Index Score to measure coronary inflammation, continues to see commercial deployment across the UK, Europe, Switzerland, and Australia. Caristo, a 2026 World Economic Forum Technology Pioneer, aims to shift cardiovascular care toward early detection and prevention.